Adagene to Participate in Investor Conferences in September
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company, has announced its participation in several upcoming investor conferences in New York City this September. The company's management will host investor meetings, and Peter Luo, Ph.D., Adagene's Chairman, CEO, and President of R&D, will present at three major events:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6
2. H.C. Wainwright 26th Annual Global Investment Conference on September 9
3. 2024 Cantor Fitzgerald Global Healthcare Conference on September 18
Live webcasts of the presentations will be available on Adagene's website, with replays accessible for at least 30 days. These conferences provide an opportunity for Adagene to showcase its platform-driven approach to discovering and developing novel antibody-based therapies.
Adagene Inc. (Nasdaq: ADAG), una società biotecnologica in fase clinica, ha annunciato la sua partecipazione a diverse conferenze per investitori che si terranno a New York City questo settembre. La direzione della società ospiterà incontri con gli investitori e Peter Luo, Ph.D., Presidente, CEO e Responsabile della R&D di Adagene, presenterà in tre eventi principali:
1. 22ª Conferenza Annuale sulla Salute Globale di Morgan Stanley il 6 settembre
2. 26ª Conferenza Annuale sugli Investimenti Globali di H.C. Wainwright il 9 settembre
3. Conferenza Globale sulla Salute di Cantor Fitzgerald 2024 il 18 settembre
Le presentazioni saranno trasmesse in diretta sul sito web di Adagene, con repliche disponibili per almeno 30 giorni. Queste conferenze offrono un'opportunità a Adagene per mettere in evidenza il suo approccio basato sulla piattaforma nella scoperta e nello sviluppo di nuove terapie anticorpali.
Adagene Inc. (Nasdaq: ADAG), una empresa biotecnológica en etapa clínica, ha anunciado su participación en varias conferencias de inversores que se llevarán a cabo en la ciudad de Nueva York este septiembre. La dirección de la empresa organizará reuniones con inversores, y Peter Luo, Ph.D., Presidente, CEO y Presidente de I+D de Adagene, presentará en tres eventos principales:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley el 6 de septiembre
2. 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright el 9 de septiembre
3. Conferencia Global de Salud de Cantor Fitzgerald 2024 el 18 de septiembre
Las presentaciones estarán disponibles en vivo a través del sitio web de Adagene, con repeticiones accesibles durante al menos 30 días. Estas conferencias brindan una oportunidad para que Adagene muestre su enfoque basado en plataformas para descubrir y desarrollar nuevas terapias basadas en anticuerpos.
Adagene Inc. (Nasdaq: ADAG)는 현재 임상 단계의 생명공학 회사로, 이번 9월 뉴욕에서 열리는 여러 투자자 회의에 참여할 것이라고 발표했습니다. 회사 경영진은 투자자 회의를 주최하며, Peter Luo, Ph.D.는 Adagene의 회장, CEO 및 R&D 사장으로서 세 가지 주요 행사에서 발표할 예정입니다:
1. 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스 9월 6일
2. H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스 9월 9일
3. 2024 캔터 피츠제럴드 글로벌 헬스케어 컨퍼런스 9월 18일
발표는 Adagene의 웹사이트에서 실시간으로 볼 수 있으며, 30일 이상 재생 가능하도록 제공됩니다. 이러한 회의는 Adagene이 항체 기반의 새로운 치료법을 발견하고 개발하는 플랫폼 중심의 접근 방식을 선보일 수 있는 기회를 제공합니다.
Adagene Inc. (Nasdaq: ADAG), une société de biotechnologie en phase clinique, a annoncé sa participation à plusieurs conférences d'investisseurs à New York ce septembre. La direction de la société organisera des réunions avec des investisseurs, et Peter Luo, Ph.D., Président, CEO et Directeur de la R&D d'Adagene, présentera lors de trois événements majeurs :
1. 22ème Conférence Annuelle de la Santé Mondiale de Morgan Stanley le 6 septembre
2. 26ème Conférence Annuelle d'Investissement Mondial de H.C. Wainwright le 9 septembre
3. Conférence Mondiale de la Santé de Cantor Fitzgerald 2024 le 18 septembre
Les présentations seront diffusées en direct sur le site Web d'Adagene, avec des rediffusions accessibles pendant au moins 30 jours. Ces conférences offrent à Adagene l'occasion de mettre en avant son approche axée sur la plateforme pour découvrir et développer de nouvelles thérapies basées sur des anticorps.
Adagene Inc. (Nasdaq: ADAG), ein biotechnologisches Unternehmen in der klinischen Phase, hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen in New York City im September angekündigt. Das Management des Unternehmens wird Investorenmeetings abhalten, und Peter Luo, Ph.D., Vorsitzender, CEO und Leiter der F&E von Adagene, wird auf drei wichtigen Veranstaltungen präsentieren:
1. 22. Morgan Stanley globale Gesundheitskonferenz am 6. September
2. 26. H.C. Wainwright globale Investorenkonferenz am 9. September
3. 2024 Cantor Fitzgerald globale Gesundheitskonferenz am 18. September
Live-Übertragungen der Präsentationen werden auf der Website von Adagene verfügbar sein, mit Wiederholungen, die mindestens 30 Tage lang zugänglich sind. Diese Konferenzen bieten Adagene die Möglichkeit, seinen plattformbasierten Ansatz zur Entdeckung und Entwicklung neuer antikörperbasierter Therapien vorzustellen.
- None.
- None.
SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor conferences in New York City. Management will host investor meetings and Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will present at the following events:
Morgan Stanley 22nd Annual Global Healthcare Conference
- Date: Friday, September 6
- Fireside Chat: 7:45 - 8:20 AM Eastern Time (ET)
H.C. Wainwright 26th Annual Global Investment Conference
- Date: Monday, September 9
- Fireside Chat: 8:30 - 9:00 AM ET
2024 Cantor Fitzgerald Global Healthcare Conference
- Date: Wednesday, September 18
- Fireside Chat: 2:30 PM - 3:00 PM ET
A live webcast of the presentations will also be accessible in the Investors section of the company’s website at https://www.adagene.com. A webcast replay will be available for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor & Media Contact
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com
FAQ
What investor conferences will Adagene (ADAG) attend in September 2024?
Who will be presenting at the investor conferences for Adagene (ADAG)?
Where can investors access the webcasts of Adagene's (ADAG) conference presentations?
What is the focus of Adagene's (ADAG) biotechnology research?
